Pluda J - Search Results

1

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.

Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W. Kurdziel K, et al. Among authors: pluda j. Clin Positron Imaging. 2000 Jul;3(4):144. doi: 10.1016/s1095-0397(00)00056-x. Clin Positron Imaging. 2000. PMID: 11150747

2

Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer.

Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL. Kurdziel KA, et al. Among authors: pluda jm. Mol Imaging Biol. 2003 Mar-Apr;5(2):86-93. doi: 10.1016/s1536-1632(03)00039-8. Mol Imaging Biol. 2003. PMID: 14499149 Clinical Trial.

3

Pharmacokinetics of thalidomide in an elderly prostate cancer population.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Figg WD, et al. Among authors: pluda j. J Pharm Sci. 1999 Jan;88(1):121-5. doi: 10.1021/js980172i. J Pharm Sci. 1999. PMID: 9874712 Clinical Trial.

4

Thalidomide neuropathy in patients treated for metastatic prostate cancer.

Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Molloy FM, et al. Among authors: pluda j. Muscle Nerve. 2001 Aug;24(8):1050-7. doi: 10.1002/mus.1109. Muscle Nerve. 2001. PMID: 11439380 Clinical Trial.

5

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. Figg WD, et al. Among authors: pluda j. Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6. doi: 10.1016/s0093-7754(01)90157-5. Semin Oncol. 2001. PMID: 11685731 Clinical Trial.

6

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. Among authors: pluda jm. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

7

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E. Figg WD, et al. Among authors: pluda jm. Clin Cancer Res. 2001 Jul;7(7):1888-93. Clin Cancer Res. 2001. PMID: 11448901 Clinical Trial.

8

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.

Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E. Bauer KS, et al. Among authors: pluda jm. Clin Cancer Res. 1999 Sep;5(9):2324-9. Clin Cancer Res. 1999. PMID: 10499600 Clinical Trial.

9

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Among authors: pluda jm. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

10

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: pluda jm. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

88 results

Search Page